Elevance Health (ELV) has been a focal point in the market with various activities shaping investor sentiment. Despite recent stock depreciation, strong fundamental components of the company have been highlighted. Both
Caprock Group LLC and
Assetmark Inc. have recently bought new positions in ELV, while
Varma Mutual Pension Insurance Co and
Wealthfront Advisers LLC upped their holdings. In contrast,
Versor Investments LP,
Oppenheimer Asset Management Inc.,
Cornerstone Investment Partners LLC,
SVB Wealth LLC and others have trimmed their stakes. ELV’s recent share price pullback has sparked a valuation debate, though Q4 earnings did beat estimates, they fell in line with expectations. The 2026 outlook indicates softer growth and higher payouts, particularly troubling given the company's recent underwhelming profit forecasts.
Zacks Research has cut Q1 EPS estimates for ELV citing these mixed metrics. ELV's push into digital health continues as it refocuses on government plans despite membership declines and a slower EPS. Analysts recommend a ‘Hold’ rating for ELV, despite a strong cash yield. The company's pricing has been viewed as misaligned given its multi-year share performance and strong cash flow valuation models. As ELV approaches Q4 earnings amidst rising costs, it will continue to be a crucial watch for investors.
Elevance Health ELV News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 11:00:10 GMT -
Rating -2
- Innovation 3
- Information 7
- Rumor -4
